Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCUIT: Nivolumab plus radiotherapy for recurrent gastric cancer
jRCTs021180002Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Ono Pharmaceutical. Primary endpoint: Disease control rate in non-irradiated lesions. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs021180002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180002.